ImmunityBio makes ANKTIVA, an approved bladder cancer treatment, and develops immune-based cancer therapies and vaccines. It last closed at $6.26 on Nov 17, up 4.68% on the day. The average 12-month price target from 2 analysts is $14.50 (+131.6% from the last close), with a high of $15.00 and a low of $14.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in IBRX, 100% of them bullish and 0% bearish. In the past 30 days there were 8 dark pool prints totaling $4.2M, the largest $1.7M.
Only 2 firms rated IBRX in the past 90 days, not enough for a consensus
Average 12-month target
$14.50
▲ 131.6% upside
Based on 2 analysts who set a price target on IBRX in the past 90 days. The average target is $14.50, with a high of $15.00 and a low of $14.00, compared with the last close of $6.26.
Highest target$15.00
Average target$14.50
Lowest target$14.00
Latest rating changes
JefferiesMaintained
Oct 15Buy$14
HC Wainwright & Co.Reiterated
Oct 15Buy$15
BTIGReiterated
May 21Buy$12
Date
Firm
Action
Rating
Price target
Oct 15
Jefferies
Maintained
Buy
$14
Oct 15
HC Wainwright & Co.
Reiterated
Buy
$15
May 21
BTIG
Reiterated
Buy
$12
Loading…
Technical Analysis
IBRX · as of the Nov 17 close · updated after every close
Turning down, nearing oversold
The stock is 23% below its 20 day and 36% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $6.24, and the nearest resistance the Pivot R1 at $6.40.
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.7%/day
Key levels
$12.4352 week high+98.6%
$8.5150 day average+35.9%
$8.19100 day average+30.8%
$7.97200 day average+27.3%
$7.7120 day average+23.2%
$7.62Swing high (Jul 31)+21.7%
$6.40Pivot R1+2.2%
$6.26Last close
$6.24Pivot−0.3%
$6.10Pivot S1−2.6%
$1.9552 week low−68.8%
Indicators
RSI (14)
35.72
Weak, oversold below 30
Neutral
MACD
-0.73
Below its signal line
Bearish
Stochastic
9.6
Near the bottom of its range
Oversold
ADX (14)
25.9
Trending down
Williams %R
-84.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-108.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−24.5%
Change over 10 sessions
Bearish
ATR (14)
$0.67
Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 20.5%/day
Key levels
$12.4352 week high+98.6%
$8.5150 day average+35.9%
$8.19100 day average+30.8%
$7.97200 day average+27.3%
$7.7120 day average+23.2%
$7.62Swing high (Jul 31)+21.7%
$6.40Pivot R1+2.2%
$6.26Last close
$6.24Pivot−0.3%
$6.10Pivot S1−2.6%
$1.9552 week low−68.8%
Indicators
RSI (14)
40.87
Middle of its range
Neutral
MACD
0.08
Below its signal line
Bearish
Stochastic
20.3
Middle of its range
Neutral
ADX (14)
30.0
Trending down
Williams %R
-90.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-174.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.9%
Change over 10 sessions
Bearish
ATR (14)
$1.28
Typical daily range, 20.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for IBRX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IBRX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IBRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBRX is in one of them and how their past IBRX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About ImmunityBio
ImmunityBio is a biological products company based in San Diego, California. Its main approved product is ANKTIVA, a treatment for bladder cancer that it sells in the United States and through partners in other regions. The company is also developing cell therapies, cancer vaccines and other treatments that work through the immune system for cancer and infectious diseases.